The FDA approved use of the 9vHPV vaccine for males aged 16-26 years, extending the previous indication that was for females aged 9-26 years and males aged 9-15 years. The current Advisory Committee on Immunization Practices’ (ACIP) 9vHPV vaccination recommendation includes males through age 21 and through age 26 years for men who have sex with men and for those immunocompromised, including with HIV infection. With this FDA approval, the ACIP recommendation for males aged 16-26 is no longer “off label.” Read the approval letter here.
More NACCHO Blogs
The Preparedness Brief provides updates and information from NACCHO’s public health preparedness portfolio.
The Word on Local Health Departments is a blog by the National Association of County and City Health Officials (NACCHO).